News
-
-
PRESS RELEASE
NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value
NanoViricides, Inc. highlights the strong effectiveness of its broad-spectrum antiviral drug NV-387 against various viruses. Expected to drive significant valuation and market share, leading to rapid regulatory approvals and early revenues -
PRESS RELEASE
Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Xenetic Biosciences expands research collaboration with TSRI to validate DNase-I data in lymphoma and leukemia models. Advancing oncology therapies with CAR T-cells -
-
-
-
-
-
-